A Call for Transparency in Research and Marketing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Call for Transparency in Research and Marketing
Broader disclosure of drug prices and conflicts of interest are central healthcare reform issues.

Pharmaceutical Technology
Volume 33, Issue 3, pp. 40-50

Disclosures on docs

States are passing laws that require manufacturers to disclose payments and gifts to healthcare professionals. Such requirements have been enacted in Minnesota, Vermont, West Virginia, Maine, and, most recently, Massachusetts. A long list of states, including California, Texas, Illinois, and New York is considering such laws. These statutes generally seek data about fees, gifts, and educational grants to healthcare providers and organizations, but policies vary considerably as to which expenditures have to be disclosed and when.

In addition, federal and state enforcement officials are including disclosure requirements in corporate integrity agreements (CIAs) negotiated with drug companies to resolve allegations of fraudulent promotional and pricing practices. Prosecutors have put an "emphasis on transparency" in industry relationships with physicians and in results from clinical trials, said US attorney Michael Loucks at CBI's Pharmaceutical Compliance Congress in January 2009.

Under a comprehensive CIA, negotiated as part of Eli Lilly's record $1.4-billion settlement involving "Zyprexa" sales and marketing, Lilly will post quarterly reports on its website about payments to physicians, including speaker and consulting fees, grants, gifts, food, and travel. Last year, Cephalon (Frazer, PA) similarly agreed to report all payments to physicians as part of its $375-million settlement with federal and state prosecutors to resolve allegations of improper marketing practices for three medications. Bristol-Myers Squibb's 2007 CIA includes requirements for reporting listed prices to state Medicaid programs to ensure accurate pricing.

Disclosure demands from prosecutors and state legislators are building industry support for federal transparency legislation that would preempt state laws. In January 2009, Senators Charles Grassley (R-IA) and Herb Kohl (D-WI) introduced an updated version of the Physician Payments Sunshine Act. The bill expands public disclosure of financial relationships between physicians and manufacturers of drugs and medical products that are covered by Medicare, Medicaid, or other government health programs. The revised bill calls for manufacturers to file reports on payments to physicians that exceed $100 a year (down from a previous $500 threshold) plus any substantial investment interests held by doctors. Companies also would compile annual reports of total payments and breakouts for each state.

Such expanded disclosure is supported by the Medicare Payment Advisory Committee (MedPAC) in its March 2009 report to Congress. The advisory group wants to collect more payment data to better assess whether industry–provider financial relations affect Medicare prescribing, drug use, and expenditures. MedPAC also wants information about drug samples distributed to doctors and other parties to determine whether providing $20 billion in free medicines each year has an identifiable impact on prescribing decisions. FDA currently requires companies to keep records on samples handed out by sales representatives to guard against illegal diversion, but does not ask for regular reporting of sampling activity.

Under the Sunshine Act, all this payment information would be stored in a national database of physician–industry relationships. Public and private payers and health plans thus would be able to uncover and assess relationships between industry payments and physicians' practice patterns. The trade-off for manufacturers is supposed to be federal preemption of state disclosure laws that require different information about payments to physicians. It's not clear how comprehensive that preemption will be in the final legislation, however. Though some MedPAC members recognize that industry–doctor relationships can help advance the development of new technology, the broad consensus is that making health professionals' links to pharmaceutical marketing known to all will discourage inappropriate relationships.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here